In the last two decades, medical researchers have made significant advances in the diagnosis and treatment of retina conditions, discovering new sight-saving treatments for diseases that once robbed patients of their vision.

At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care — a value instilled by the pioneering physicians who founded our practice more than 50 years ago. That is why our physicians have participated in more than 100 national clinical trials over the past 20+ years, offering our patients access to promising new treatments for a variety of retina conditions, including age-related macular degeneration (AMD), ocular melanoma (cancer), diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and uveitis.

We recently opened 10 new clinical trials:

Diabetic Macular Edema, Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO)

  • EYE-TIE (Dallas Main, Plano) — A two-part study of IVT EYE201 in participants with macular edema following branch retinal vein occlusion (BRVO), and in participants with either diabetic macular edema (DME) or neovascular (wet) age-related macular degeneration (AMD).

Diabetic Macular Edema, Wet Age-Related Macular Degeneration (AMD)

  • Ollin (Arlington, Dallas Main, Plano) — A Phase Ib study of two different formulations of IV OLN234 in adult participants with either diabetic macular edema (DME) or neovascular (wet) age-related macular degeneration.

Diabetic Macular Edema

  • Part 5 (Arlington, Dallas Main) — A Phase I/II study to evaluate RO7446603 administered alone and/or in combination with aflibercept or faricimab in patients with diabetic macular edema.

Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)

  • Sienna (Dallas Main) — A multi-center, Phase III study of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone in participants with geographic atrophy secondary to age-related macular degeneration (AMD).

Wet Macular Degeneration

  • Artemis (Dallas Main) — A Phase III study to evaluate Lxo-vec in participants with neovascular (wet) age-related macular degeneration (AMD).
  • 4D (Arlington) — A Phase III single intravitreal injection of 4D-150 in adults with macular neovascularization secondary to age-related macular degeneration (AMD).
  • Lucia (Arlington) — A Phase III study of EYP-1901, a TKI, compared to aflibercept in subjects with wet age-related macular degeneration (AMD).
  • NOVA-1 (Arlington, Dallas Main) — A Phase II study of sustained release implant in participants with neovascular (wet) age-related macular degeneration (AMD).
  • Sanofi (Dallas Main) — A Phase I/II dose escalation and dose expansion study to evaluate a one-time intravitreal dose of SAR402663 in participants with neovascular (wet) age-related macular degeneration (AMD).
  • Sol-R (Dallas Main, Arlington) — A Phase III study to evaluate intravitreal OTX-TKI in subjects with neovascular (wet) age-related macular degeneration (AMD).

We currently have a total of 36 open studies. Click here to view all of our actively enrolling clinical trials.

For more information or to determine eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.